Paroxetine


Curated chemical-gene interactions from CTD
Entrez gene IDGene symbolInteraction typeReference
1244 ABCC2 Increases expression PMID:12524417
1431 CS Increases activity PMID:20347017
1555 CYP2B6 Decreases activity PMID:21915887
1565 CYP2D6 Decreases activity PMID:12173784; PMID:12378847; PMID:15632378; PMID:15860655; PMID:19593786; PMID:21915887; PMID:26599973
1588 CYP19A1 Decreases activity PMID:26162595
1956 EGFR Increases activity PMID:19662385
23237 ARC Increases expression PMID:14580947
2875 GPT Increases activity PMID:36740106
3061 HCRTR1 Increases expression PMID:21157932
3062 HCRTR2 Increases expression PMID:21157932
3269 HRH1 Increases expression PMID:21157932
3351 HTR1B Decreases expression PMID:10861803
3358 HTR2C Increases activity PMID:19662385
3553 IL1B Affects expression PMID:32020710
3586 IL10 Increases expression PMID:32020710
3605 IL17A Decreases expression PMID:32020710
3667 IRS1 Decreases activity PMID:17728140
367 AR Decreases activity PMID:25752796
3717 JAK2 Increases expression PMID:32020710
3760 KCNJ3 Decreases activity PMID:17072103
3762 KCNJ5 Decreases activity PMID:17072103
3763 KCNJ6 Decreases activity PMID:17072103
5196 PF4 Decreases expression PMID:10770450
5473 PPBP Decreases expression PMID:10770450
5594 MAPK1 Increases activity PMID:19662385
5595 MAPK3 Increases activity PMID:19662385
5599 MAPK8 Increases activity PMID:17728140
5743 PTGS2 Decreases expression PMID:17499975
627 BDNF Increases expression PMID:21301813
6532 SLC6A4 Decreases activity PMID:16272152
6532 SLC6A4 Decreases expression PMID:10575045; PMID:16055263
6774 STAT3 Affects expression PMID:17499975; PMID:32020710
7020 TFAP2A Increases expression PMID:28844482
7124 TNF Decreases expression PMID:32020710
7422 VEGFA Increases expression PMID:21301813
7425 VGF Increases expression PMID:21301813
836 CASP3 Increases activity PMID:17174998; PMID:28482088
841 CASP8 Increases activity PMID:28482088
842 CASP9 Increases activity PMID:28482088
847 CAT Decreases activity PMID:36740106

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.